Systematic identification of combinatorial drivers and targets in cancer cell lines.

There is an urgent need to elicit and validate highly efficacious targets for combinatorial intervention from large scale ongoing molecular characterization efforts of tumors. We established an in silico bioinformatic platform in concert with a high throughput screening platform evaluating 37 novel...

Full description

Bibliographic Details
Main Authors: Adel Tabchy, Nevine Eltonsy, David E Housman, Gordon B Mills
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3618473?pdf=render
id doaj-26b31b693c9d4904aa0a23ddb0e88b46
record_format Article
spelling doaj-26b31b693c9d4904aa0a23ddb0e88b462020-11-25T02:05:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6033910.1371/journal.pone.0060339Systematic identification of combinatorial drivers and targets in cancer cell lines.Adel TabchyNevine EltonsyDavid E HousmanGordon B MillsThere is an urgent need to elicit and validate highly efficacious targets for combinatorial intervention from large scale ongoing molecular characterization efforts of tumors. We established an in silico bioinformatic platform in concert with a high throughput screening platform evaluating 37 novel targeted agents in 669 extensively characterized cancer cell lines reflecting the genomic and tissue-type diversity of human cancers, to systematically identify combinatorial biomarkers of response and co-actionable targets in cancer. Genomic biomarkers discovered in a 141 cell line training set were validated in an independent 359 cell line test set. We identified co-occurring and mutually exclusive genomic events that represent potential drivers and combinatorial targets in cancer. We demonstrate multiple cooperating genomic events that predict sensitivity to drug intervention independent of tumor lineage. The coupling of scalable in silico and biologic high throughput cancer cell line platforms for the identification of co-events in cancer delivers rational combinatorial targets for synthetic lethal approaches with a high potential to pre-empt the emergence of resistance.http://europepmc.org/articles/PMC3618473?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Adel Tabchy
Nevine Eltonsy
David E Housman
Gordon B Mills
spellingShingle Adel Tabchy
Nevine Eltonsy
David E Housman
Gordon B Mills
Systematic identification of combinatorial drivers and targets in cancer cell lines.
PLoS ONE
author_facet Adel Tabchy
Nevine Eltonsy
David E Housman
Gordon B Mills
author_sort Adel Tabchy
title Systematic identification of combinatorial drivers and targets in cancer cell lines.
title_short Systematic identification of combinatorial drivers and targets in cancer cell lines.
title_full Systematic identification of combinatorial drivers and targets in cancer cell lines.
title_fullStr Systematic identification of combinatorial drivers and targets in cancer cell lines.
title_full_unstemmed Systematic identification of combinatorial drivers and targets in cancer cell lines.
title_sort systematic identification of combinatorial drivers and targets in cancer cell lines.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description There is an urgent need to elicit and validate highly efficacious targets for combinatorial intervention from large scale ongoing molecular characterization efforts of tumors. We established an in silico bioinformatic platform in concert with a high throughput screening platform evaluating 37 novel targeted agents in 669 extensively characterized cancer cell lines reflecting the genomic and tissue-type diversity of human cancers, to systematically identify combinatorial biomarkers of response and co-actionable targets in cancer. Genomic biomarkers discovered in a 141 cell line training set were validated in an independent 359 cell line test set. We identified co-occurring and mutually exclusive genomic events that represent potential drivers and combinatorial targets in cancer. We demonstrate multiple cooperating genomic events that predict sensitivity to drug intervention independent of tumor lineage. The coupling of scalable in silico and biologic high throughput cancer cell line platforms for the identification of co-events in cancer delivers rational combinatorial targets for synthetic lethal approaches with a high potential to pre-empt the emergence of resistance.
url http://europepmc.org/articles/PMC3618473?pdf=render
work_keys_str_mv AT adeltabchy systematicidentificationofcombinatorialdriversandtargetsincancercelllines
AT nevineeltonsy systematicidentificationofcombinatorialdriversandtargetsincancercelllines
AT davidehousman systematicidentificationofcombinatorialdriversandtargetsincancercelllines
AT gordonbmills systematicidentificationofcombinatorialdriversandtargetsincancercelllines
_version_ 1724935760588570624